Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06436144 | Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC | PHASE2 | NOT YET_RECRUITING | 93 | — | — | Jun 1, 2024 | Dec 1, 2029 | May 30, 2024 | - | — |
| NCT06018688 | Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients. | PHASE2 | NOT YET_RECRUITING | 44 | — | — | Sep 15, 2023 | Sep 1, 2026 | Sep 21, 2023 | - | — |
To evaluate the efficacy of osimertinib combined with etoposide as first-line treatment in patients with osimertinib-resistant or -insensitive, advanced EGFR-mutant non-small cell lung cancer. ORR will be defined as the proportion of patients achieving complete response (CR) or partial response (PR) according to RECIST v1.1 criteria.
MPR refers to the percentage of residual viable tumor cells within the tumor bed after neoadjuvant treatment, with a threshold of ≤10%, regardless of the presence of residual viable tumor cells in the lymph nodes.
| Arm | Type | Description |
|---|---|---|
| Osimertinib Combined With Etoposide Soft Capsule | EXPERIMENTAL | - |
| osimertinib and aspirin | EXPERIMENTAL | Osimertinib and Aspirin starting at a dose of 80 mg and 100mg once a day, orally with meals.The participants will undergo a two-month combination therapy, unless there is tumor progression (worsening) or intolerable toxic reactions that necessitate early termination of the drug treatment. Aspirin will be discontinued one week prior to the surgery. |
| Name | Type | Description |
|---|---|---|
| Osimertinib | DRUG | Etoposide Soft Capsules Dosage：25mg/tablet, 2 tablets/time, taken continuously for 21 days, and stopped for one week. Osimertinib Dosage：80mg/tablet, 1 tablet/time, QD, taken for two cycles. |
| Aspirin | DRUG | Aspirin, also known as acetylsalicylic acid (ASA), is a verysafe medication used to treat pain,fever, or inflammation. |
Inclusion Criteria: 1. Age 18 to 79 years. 2. Locally advanced (stage IIIB) or metastatic (stage IV) EGFR-mutant NSCLC. 3. Harboring an EGFR sensitizing mutation (Exon 19 deletion or L858R). 4. Received at least two cycles of first-line osimertinib treatment, with a best response of stable disease ...